Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1986 Oct;25(5):167-71.

Clinical results of immunoscintigraphy in a variety of malignant tumors with special reference to immunohistochemistry

H J Biersack, A Bockisch, P Oehr, A Knoblich, J Hartlapp, H Biltz, N Jaeger, O Bellmann, J Vogel, B Björklund, et al.
  • PMID: 3540857

Clinical results of immunoscintigraphy in a variety of malignant tumors with special reference to immunohistochemistry

H J Biersack et al. Nuklearmedizin. 1986 Oct.

Abstract

Radioimmunoscintigraphy was performed in 52 patients with a variety of malignant tumors (colorectal, melanoma, lung, testicular, ovarian, bladder, carcinoid). Respective antibodies or their F(ab')2 fragments against CEA (n = 23), melanoma antigen 225.28 S (n = 18), TPA (n = 4), beta HCG (n = 5) and HMFG2 (n = 2) were selected by immunohistochemistry of the primary tumor. Most patients were suspected of recurrence or of hitherto unknown distant or local metastases. Overall accuracy was 61% (32/52). False negatives amounted to 33% (17/52). Useful additional clinical information-not available by CT, ultrasonics or serum levels of tumor markers-was obtained in 17 out of 52 patients (= 33%). From these results it seems obvious that antibodies used for radioimmunoscintigraphy should be selected on the basis of immunohistochemistry.

PubMed Disclaimer

MeSH terms